COVID-19 Anti-Viral Medication

Harbison’s first shipment of COVID-19 anti-viral medication has arrived! It may be prescribed by a GP to treat infection, and consists of a course of four (4) tablets, twice-a-day, for five (5) days.

We believe the possibility of an effective treatment will permit a reassessment of the risks of COVID-19 in residential aged care.

What you need to know about Lagevrio

  • Lagevrio (Molnupiravir) is an oral treatment for COVID-19, which means it is administered in the form of a tablet.
  • Lagevrio was approved by the Therapeutic Goods Administration on 18 January 2022 and pending PBS approval is being preplaced by the Australian Government in residential Aged Care facilities.
  • Lagevrio is an S4 medicine, which means it requires a prescription from a GP.
  • Lagevrio can be effective in treating people with mild to moderate COVID-19 symptoms, who have no need for supplemental oxygen due to COVID-19, and who are at high risk of progression to hospitalisation or death.
  • Lagevrio should be administered within five (5) days of symptom onset.
  • A course of Lagevrio consists of four (4) tablets every 12-hours for five (5) days (40 tablets in total), swallowed with water with or without food.
  • Consent is required for the administration of Lagevrio.
  • Until Lagevrio is registered with the PBS, each prescription must be notified by the GP to the Commonwealth.

More information can be found via the link below.

Lageviro Molnupiravir Factsheet (February 2022)